IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

TODOERTI, KATIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 21.762
NA - Nord America 12.680
AS - Asia 11.414
SA - Sud America 928
AF - Africa 267
OC - Oceania 62
Continente sconosciuto - Info sul continente non disponibili 8
Totale 47.121
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.321
DE - Germania 10.475
CN - Cina 4.340
GB - Regno Unito 4.262
SG - Singapore 2.874
IT - Italia 2.122
SE - Svezia 1.099
RU - Federazione Russa 1.089
HK - Hong Kong 871
VN - Vietnam 757
FR - Francia 679
BR - Brasile 653
IN - India 630
BD - Bangladesh 441
UA - Ucraina 419
NL - Olanda 391
TR - Turchia 372
IE - Irlanda 361
KR - Corea 346
FI - Finlandia 302
CA - Canada 259
EU - Europa 226
JP - Giappone 197
ID - Indonesia 190
CO - Colombia 135
DK - Danimarca 112
PL - Polonia 108
EG - Egitto 84
CI - Costa d'Avorio 66
AU - Australia 55
IQ - Iraq 55
AR - Argentina 54
GR - Grecia 51
MX - Messico 49
MY - Malesia 45
BE - Belgio 40
AT - Austria 39
ES - Italia 33
ZA - Sudafrica 33
CH - Svizzera 28
PH - Filippine 27
TW - Taiwan 27
EC - Ecuador 26
RO - Romania 26
PK - Pakistan 24
UZ - Uzbekistan 24
MA - Marocco 22
IR - Iran 20
NP - Nepal 20
NO - Norvegia 19
SA - Arabia Saudita 19
TH - Thailandia 19
CZ - Repubblica Ceca 18
VE - Venezuela 17
AE - Emirati Arabi Uniti 16
PY - Paraguay 16
JO - Giordania 14
TN - Tunisia 14
CL - Cile 13
AL - Albania 11
KE - Kenya 11
BG - Bulgaria 10
HU - Ungheria 9
IL - Israele 9
JM - Giamaica 9
AZ - Azerbaigian 8
PT - Portogallo 8
RS - Serbia 8
DZ - Algeria 6
HN - Honduras 6
HR - Croazia 6
KW - Kuwait 6
LU - Lussemburgo 6
MD - Moldavia 6
MO - Macao, regione amministrativa speciale della Cina 6
NZ - Nuova Zelanda 6
PS - Palestinian Territory 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
BO - Bolivia 5
CR - Costa Rica 5
CY - Cipro 5
GE - Georgia 5
LT - Lituania 5
SC - Seychelles 5
AM - Armenia 4
BH - Bahrain 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
OM - Oman 4
QA - Qatar 4
ET - Etiopia 3
GA - Gabon 3
GT - Guatemala 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
LI - Liechtenstein 3
LK - Sri Lanka 3
MN - Mongolia 3
Totale 47.274
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 7.823
Southend 3.788
Singapore 1.592
Ashburn 1.152
Beijing 975
Hong Kong 794
Chandler 787
Hanover 731
Milan 692
Boise 652
Seattle 643
San Jose 585
Wilmington 467
Fairfield 460
Princeton 460
Council Bluffs 422
Dallas 367
Dublin 356
Jacksonville 332
Dearborn 326
Woodbridge 288
Houston 282
Los Angeles 262
Nanjing 262
Ho Chi Minh City 223
Ann Arbor 222
Bengaluru 222
Shanghai 212
Guangzhou 198
Lauterbourg 197
Mountain View 197
New York 197
Cambridge 193
Redmond 184
Hanoi 171
Somerville 162
Santa Clara 146
Hefei 145
Toronto 145
Buffalo 141
Des Moines 141
Moscow 140
Andover 135
Jakarta 131
Serra 131
Sakarya 121
Bogotá 119
Helsinki 118
Jinan 111
Boardman 109
Tokyo 107
Berlin 100
Shenyang 93
Nanchang 91
Phoenix 86
Tianjin 82
Warsaw 80
Changsha 79
Columbus 79
Redwood City 69
Abidjan 66
Rome 66
Hangzhou 65
Cangzhou 64
The Dalles 63
Hebei 60
Wuhan 60
Zhengzhou 60
Eitensheim 55
Seoul 55
São Paulo 55
Saint Petersburg 54
Matera 51
San Diego 51
London 49
Athens 47
Munich 47
Brescia 45
Chengdu 44
Chicago 44
Turin 44
Fuzhou 43
Naples 43
Hamburg 38
Bitonto 37
Shenzhen 37
Grafing 36
Pisa 36
Roxbury 36
Atlanta 35
Dong Ket 35
Nuremberg 35
Odernheim 35
Orofino 35
Brussels 33
Da Nang 33
Kiez 33
Silver Spring 33
Kunming 32
Payette 32
Totale 31.397
Salva come PNG Salva come JPEG
Nome #
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 1.016
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies 778
Pathogenicity of in-vivo generated intestinal Th17 lymphocytes is IFNγ dependent 534
COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death 513
Clinical-biological characterization of variant B chronic lymphocytic leukemia, characterized by a mantle cell lymphoma-like immunophenotype, t(11;14)(q13;q32) negative 512
Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma 474
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 465
Halting the FGF/FGFR axis leads to anti-tumor activity in Waldenström's Macroglobulinemia by silencing MYD88 459
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 434
A GBM-like V-ATPase signature directs cell-cell tumor signaling and reprogramming via large oncosomes 407
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 400
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 398
A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma 395
Identification of specific transcriptional patterns associated with hyperdiploidy in multiple myeloma 385
Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma 372
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns 359
Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing 352
A distinctive trascriptional profile characterizes the chromosome 17p loss in B-cell chronic lymphocytic leukemia 339
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 338
The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA 333
Notch signaling drives multiple myeloma induced osteoclastogenesis 331
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome 328
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche 327
The expression pattern of small nucleolar and small cajal body-specific RNAS characterizes distinct molecular subtypes of multiple myeloma 324
Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma 321
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma 316
Analisi del numero di copie e sequenza del DNA in campioni sequenziali di melanoma alla diagnosi e recidiva=DNA copy number and whole-exome sequencing analyses in sequential myeloma samples at diagnosis and relapse 315
Disentangling the microRNA regulatory milieu in multiple myeloma : integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients 313
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias : implication for MEK-ERK pathway activation 309
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 309
Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins 302
Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line 302
DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification 291
Analysis of CD44 expression in monoclonal gammopathies : correlation between gene expression level and flow cytometry findings 289
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia 289
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 289
Genome-wide approach identify recurrent 8p21.2 loss in more aggressive form of primary plasma-cell leukemia 284
Bone microenvironment cells reveal a different gene expression profiling in multiple myeloma patients as compared to healthy subjects : potential relationship with the bone status 281
Integrative genomic analysis of trisomy 12 abnormality in B-cell chronic lymphocytic leukemia 276
Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma 276
A novel fish-based normalization procedure for whole genome microarrays detecting accurate local copy numbers : application to multiple myeloma 275
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature 273
miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma 273
Identification of specific transcriptional patterns associated with hyperdiploidy in multiple myeloma 272
A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma : an integrated genomics approach reveals a wide gene dosage effect 271
The role of notch pathway in multiple myeloma progression toward IL-6 independence 269
Impact of Host Genes and Strand Selection on miRNA and miRNA* Expression 268
Multiple myeloma-associated drug resistance : targeting the Notch pathway 266
Notch targeting prevents multiple myeloma associated osteoclastogenesis 266
Establishment of an interlukin-6 independent variant (CMA-03/06) of the human myeloma cell line CMA-03 : biological molecular characterization by a genomic integrative analisys 265
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles 264
Molecular and transcriptional characterization of 17P loss in B-cell chronic lymphocytic leukemia 262
Bone marrow-mediated drug resistance is promoted by Jagged-induced notch pathway in multiple myeloma 262
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening 260
Bone marrow-mediated drug resistance is promoted by Jagged-induced Notch signaling in multiple myeloma 260
Molecular classification and pharmacogenetics of primary plasma cell leukemia: an initial approach toward precision medicine 259
Establishment of an interlukin-6 independent variant (CMA-03/06) of the human myeloma cell line CMA-03 : biological and molecular characterization by a genomic integrative analisys 255
Bone microenvironment cells reveals a different gene expression profyling in multiple myeloma patients in relation to the bone status 255
Molecular definition of 17P11-P12 amplification in multiple myeloma 254
Dioxin exposure of human CD34(+) hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects 254
In silico characterization of miRNA and long non-coding RNA interplay in multiple myeloma 253
The Notch pathway controls multiple myeloma crosstalk with the osteoclastogenic niche 251
Jagged-induced notch signaling promotes endogenous and bone marrow-mediated drug resistance in multiple myeloma 251
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome 250
LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems? 250
Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma 245
Biological and molecular characterization by integrative genomics approach of CMA-03/06, a newly established interleukin-6 independent variant of the CMA-03 human myeloma cell line 243
Establishment of an interlukin-6 independent variant (CMA-03/06) of the human myeloma cell line CMA-03 : biological and molecular characterization by a genomic integrative analisys 240
A novel fish-based normalization procedure for whole genome microarrays detection accurate local copy numbers : application to multiple myeloma 238
Integrative genomic analysis of primary plasma cell leukemia revealed strong gene and microrna dosage effect 238
A retained transcriptomic profile characterizes CD138+ cells in the short time progression from smoldering to active multiple myeloma 237
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 237
The investigation of genomic profiles in primary plasma cell leukemias by means of an integrative microarray approach 236
ESTABLISHMENT OF AN INTERLEUKIN-6 INDEPENDENT VARIANT (CMA-03/06) OF THE HUMAN MYELOMA CELL LINE CMA-03 : BIOLOGICAL AND MOLECULAR CHARACTERIZATION BY A GENOMIC INTEGRATIVE ANALYSIS 236
Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs 231
Gene expression profiling of multiple myeloma : implications for a molecular classification of the disease 230
Notch signaling and multiple myeloma: challenging endogenous and bone marrow-mediated drug resistance 230
The immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and rankl/opg ratio in myeloma microenvironment targeting the expression of adhesion molecules 229
The investigation of genomic profiles in primary plasma cell leukemias by means of an integrative microarray approach 229
Global microrna expression profiling in multiple myeloma identifies deregulated patterns associated with distinct molecular groups 228
Genome-wide DNA copy number analysis by SNP arrays of B-cell chronic lymphocytic leukemia reveals the presence of novel molecular lesions 227
Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma 226
Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia 225
Notch pathway promotes multiple myeloma cell IL-6 independence 225
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in multiple myeloma patients 223
Integrative genomic approach identifies deregulated micrornas in human myeloma cell lines 223
A patient-adapted pilot study of lenalidomide in combination with low dose dexamethasone (LD) as initial therapy for a primary plasma cell leukemia (PPCL) 223
Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia 222
Dissecting the biological relevance and clinical impact of lncrna miat in multiple myeloma 222
Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines 221
Are the myeloma bone microevironment cells tumoral or not? 219
Transcriptional features of 1Q in multiple myeloma 218
The investigation of genomic profiles in plasma cell leukemias by means of an integrative microarray approach 218
Reconstruction of transcriptional regulatory networks in multiple myeloma 217
PRO-APOPTOTIC EFFECT OF A NEW SMAC-MIMETIC ON B-CLL CELLS IN VITRO 217
In vitro anti-leukaemia activity of sphingosine kinase inhibitor 216
Understanding the interaction of human cancer cells with the surrounding microenvironment: the new challenge in modern oncology 216
Global microrna expression profiling in multiple myeloma identifies deregulated patterns associated with distinct molecular groups 215
Integrative Genomic Approach Identifies Deregulated MicroRNAs in Human Myeloma Cell Lines 214
Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion 214
Totale 29.801
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.129
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.129
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.145 0 0 0 0 0 0 0 0 0 0 802 343
2021/20223.690 299 128 188 264 372 295 372 262 459 301 212 538
2022/20233.207 454 293 273 298 377 604 89 192 317 72 164 74
2023/20247.225 80 161 112 177 614 300 1.099 999 493 972 1.059 1.159
2024/20257.242 1.019 977 852 816 323 222 197 526 306 462 418 1.124
2025/20269.573 971 680 927 849 933 675 1.185 498 1.055 653 1.147 0
Totale 48.949